1. Dietary cholesterol supplementation and inhibitory factor 1 serum levels in two dizygotic Smith-Lemli-Opitz syndrome twins: a case report
- Author
-
Maria Teresa Loverro, Elvira Favoino, Anna Maria Isdraele Romano, Maurizio Delvecchio, Simonetta Simonetti, Biagio Rapone, Edoardo Di Naro, Graziana De Carlo, Simona Fecarotta, Antonio Gnoni, and Federica Taurino
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Inhibitory factor 1 ,Reductase ,Inhibitory postsynaptic potential ,Cholesterol, Dietary ,03 medical and health sciences ,chemistry.chemical_compound ,Smith-Lemli-Opitz syndrome ,0302 clinical medicine ,Neurodevelopmental disorder ,Internal medicine ,Case report ,medicine ,Twins, Dizygotic ,Humans ,Cholesterol intake ,Mitochondrial protein ,business.industry ,Cholesterol ,lcsh:RJ1-570 ,Infant ,Proteins ,lcsh:Pediatrics ,medicine.disease ,Lipids ,030104 developmental biology ,Endocrinology ,chemistry ,Smith–Lemli–Opitz syndrome ,Female ,lipids (amino acids, peptides, and proteins) ,business ,030217 neurology & neurosurgery ,Dietary Cholesterol - Abstract
Background Smith-Lemli-Opitz syndrome (SLOS) is a rare genetic neurodevelopmental disorder caused by the defect in the 7-dehydrocholesterol reductase. This defect leads to the deficiency of cholesterol biosynthesis with accumulation of 7-dehydrocholesterol. Inhibitory factor 1 (IF1) is a well-known mitochondrial protein. Recently, it has been discovered in the human serum where it is reported to be involved in the HDL-cholesterol intake. Here we report the IF1 presence in the serum of two paediatric SLOS dizygotic twins treated with dietary cholesterol supplementation. Case presentation The patients showed a typical phenotype. They started dietary supplementation with cholesterol when 2 months old. The cholesterol intake was periodically titrated on the basis of weight increase and the twin 1 required a larger supplementation than the twin 2 during the follow-up. When 6.4-year-old, they underwent IF1 assay that was 7-fold increased in twin 2 compared to twin 1 (93.0 pg/ml vs 13.0 pg/ml, respectively). Conclusions We report, for the first time, the presence of circulating IF1 in the serum of SLOS patients, showing different levels among them. Our findings confirm that IF1 could be a novel research target in cholesterol-related disorders and also in SLOS, and could contribute to the general debate on IF1 as a new modulator of cholesterol levels.
- Published
- 2020